Researchers have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with ...

Dr. Jacob Sands, who is a thoracic oncologist at Dana-Farber Cancer Institute and a spokesperson with the Lung Cancer ...

The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for certain adults ...

Osimertinib, a new targeted therapy, has significantly improved outcomes for patients with Stage Three Non-Small Cell Lung ...

Exploring the relationship between cancer cells and nerve cells, which can signal tumors to grow, could unearth ways to slow disease.

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

UD News The National Institutes of Health has awarded nearly a half-million dollars to two University of Dayton researchers ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...

For patients with non-small cell lung cancer, stereotactic ablative radiotherapy offers long-term survival outcomes comparable to surgery.